ENaC-mediated effects assessed by MRI in a rat model of hypertonic saline-induced lung hydration

British Journal of Pharmacology

Volumn 160, Issue 4, 2010, Pages 1008-1015

  Ble F X ^a,c   Cannet, C ^a   Collingwood, S ^b   Danahay, H ^b   Beckmann, N ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c Toronto Centre for Phenogenomics   (Canada)

Author keywords

Amiloride; Aquaporin; Cystic fibrosis; Cystic fibrosis transmembrane regulator; Epithelial sodium channel; Imaging; Lung; Magnetic resonance imaging; Molecular imaging; Mucus; Mucus clearance

Indexed keywords

ALPHA 1 ANTITRYPSIN; AMILORIDE; APROTININ; EPITHELIAL SODIUM CHANNEL; GUANIDINE DERIVATIVE; N (3,5 DIAMINO 6 CHLOROPYRAZINE 2 CARBONYL) N' 4 [4 [2,3 DIHYDROPROPOXYPHENYL]BUTYL]GUANIDINE; SERINE PROTEINASE INHIBITOR; SODIUM CHLORIDE; UNCLASSIFIED DRUG; EPITHELIAL SODIUM CHANNEL BLOCKING AGENT; N-(3,5-DIAMINO-6-CHLOROPYRAZINE-2-CARBONYL)-N'-(4-(4-(2,3-DIHYDROXYPROPOXY)PHENYL)BUTYL)GUANIDINE; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE; SODIUM CHANNEL BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FLUID TRANSPORT; IN VIVO STUDY; LUNG DISEASE; LUNG FLUID; LUNG HYDRATION; MALE; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSMOSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SIGNAL PROCESSING; ANIMAL; BODY WATER; BROWN NORWAY RAT; CHEMISTRY; CYSTIC FIBROSIS; DOSE RESPONSE; DRUG EFFECTS; FLUID SHIFT; INHALATIONAL DRUG ADMINISTRATION; LUNG; LUNG EXTRAVASCULAR FLUID; MUCOCILIARY CLEARANCE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RESPIRATORY TRACT MUCOSA; TIME;

ADMINISTRATION, INHALATION; ALPHA 1-ANTITRYPSIN; AMILORIDE; ANIMALS; APROTININ; BODY WATER; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL SODIUM CHANNEL BLOCKERS; EPITHELIAL SODIUM CHANNELS; EXTRAVASCULAR LUNG WATER; FLUID SHIFTS; GUANIDINES; LUNG; MAGNETIC RESONANCE IMAGING; MALE; MUCOCILIARY CLEARANCE; PROTEASE INHIBITORS; PYRAZINES; RATS; RATS, INBRED BN; RESPIRATORY MUCOSA; SALINE SOLUTION, HYPERTONIC; SODIUM CHANNEL BLOCKERS; TIME FACTORS;

EID: 77952834551     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00747.x     Document Type: Article

References (31)

1. Alexander SPH, Mathie A, Peters JA (2008). Guide to receptors and channels (GRAC). Br J Pharmacol 153 (Suppl. 2 S1 S209.
2. Allard JB, Poynter ME, Marr KA, Cohn L, Rincon M, Whittaker LA (2006). Aspergillus fumigatus generates an enhanced Th2-biased immune response in mice with defective cystic fibrosis transmembrane conductance regulator. J Immunol 177 : 5186 5194.
3. App EM, King M, Helfesrieder R, Köhler D, Matthys H (1990). Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy. Am Rev Respir Dis 141 : 605 612.
4. Beckmann N, Tigani B, Ekatodramis D, Borer R, Mazzoni L, Fozard JR (2001). Pulmonary edema induced by allergen challenge in the rat: noninvasive assessment by magnetic resonance imaging. Magn Reson Med 45 : 88 95.
5. Beckmann N, Tigani B, Sugar R, Jackson AD, Jones G, Mazzoni L et al 2002). Noninvasive detection of endotoxin-induced mucus hypersecretion in rat lung by MRI. Am J Physiol Lung Cell Mol Physiol 283 : L22 L30.
6. Blé FX, Cannet C, Zurbruegg S, Karmouty-Quintana H, Bergmann R, Frossard N et al 2008). Allergen-induced lung inflammation in actively sensitized mice assessed with MR imaging. Radiology 248 : 834 843.
7. Boucher RC (2007). Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med 58 : 157 170.
8. Bowler IM, Kelman B, Worthington D, Littlewood JM, Watson A, Conway SP et al 1995). Nebulised amiloride in respiratory exacerbations of cystic fibrosis: a randomised controlled trial. Arch Dis Child 73 : 427 430.
9. Bridges RJ, Newton BB, Pilewski JM, Devor DC, Poll CT, Hall RL (2001). Na+ transport in normal and CF human bronchial epithelial cells is inhibited by BAY 39-9437. Am J Physiol Lung Cell Mol Physiol 281 : L16 L23.
10. Coote KJ, Atherton H, Young A, Sugar R, Burrows R, Smith NJ et al 2008). The guinea-pig tracheal potential difference as an in vivo model for the study of epithelial sodium channel function in the airways. Br J Pharmacol 155 : 1025 1033.
11. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC (2006). Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 354 : 241 250.
12. Donaldson SH, Hirsh A, Li DC, Holloway G, Chao J, Boucher RC et al 2002). Regulation of the epithelial sodium channel by serine proteases in human airways. J Biol Chem 277 : 8338 8345.
13. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB et al 2006). A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 354 : 229 240.
14. Forteza R, Lieb T, Aoki T, Savani RC, Conner GE, Salathe M (2001). Hyaluronan serves a novel role in airway mucosal host defense. FASEB J 15 : 2179 2186.
15. Hirsh AJ (2002). Altering airway surface liquid volume: inhalation therapy with amiloride and hyperosmotic agents. Adv Drug Deliv Rev 54 : 1445 1462.
16. Hirsh AJ, Zhang J, Zamurs A, Fleegle J, Thelin WR, Caldwell RA et al 2008). Pharmacological properties of N-(3,5-diamino-6-chloropyrazine-2-carbonyl) -N′-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease. J Pharmacol Exp Ther 325 : 77 88.
17. Hofmann T, Senier I, Bittner P, Hüls G, Schwandt HJ, Lindemann H (1997). Aerosolized amiloride: dose effect on nasal bioelectric properties, pharmacokinetics, and effect on sputum expectoration in patients with cystic fibrosis. J Aerosol Med 10 : 147 158.
18. Karmouty-Quintana H, Blé FX, Cannet C, Zurbruegg S, Fozard JR, Page CP et al 2008). In vivo pharmacological evaluation of compound 48/80-induced airways oedema by MRI. Br J Pharmacol 154 : 1063 1072.
19. Kemp PJ, Kim KJ (2004). Spectrum of ion channels in alveolar epithelial cells: implications for alveolar fluid balance. Am J Physiol Lung Cell Mol Physiol 287 : L460 L464.
20. Kleyman TR, Cragoe EJ Jr. (1988). Amiloride and its analogs as tools in the study of ion transport. J Membr Biol 105 : 1 21.
21. Knowles MR, Church NL, Waltner WE, Yankaskas JR, Gilligan P, King M et al 1990). A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 322 : 1189 1194. (Pubitemid 20137850)
22. Knowles M, Gatzy J, Boucher R (1981). Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med 305 : 1489 1495.
23. Levin MH, Sullivan S, Nielson D, Yang B, Finkbeiner WE, Verkman AS (2006). Hypertonic saline therapy in cystic fibrosis: evidence against the proposed mechanism involving aquaporins. J Biol Chem 281 : 25803 25812.
24. Planès C, Caughey GH (2007). Regulation of the epithelial Na+ channel by peptidases. Curr Top Dev Biol 78 : 23 46.
25. Ripoll J, Ntziachristos V, Cannet C, Babin AL, Kneuer R, Gremlich HU et al 2008). Investigating pharmacology in vivo using magnetic resonance and optical imaging. Drugs R D 9 : 277 306.
26. Rudin M, Weissleder R (2003). Molecular imaging in drug discovery and development. Nat Rev Drug Discov 3 : 123 131.
27. Simchowitz L, Kleyman TR, Cragoe EJ Jr. (1992). An overview of the structure-activity relationships in the amiloride series. In : Cragoe EJ Jr., Kleyman TR, Simchowitz L (eds). Amiloride and Its Analogs: Unique Cation Transport Inhibitors. Wiley-VCH
28. Tarran R, Grubb BR, Parsons D, Picher M, Hirsh AJ, Davis CW et al 2001). The CF salt controversy: in vivo observations and therapeutic approaches. Mol Cell 8 : 149 158.
29. Tarran R, Trout L, Donaldson SH, Boucher RC (2006). Soluble mediators, not cilia, determine airway surface liquid volume in normal and cystic fibrosis superficial airway epithelia. J Gen Physiol 127 : 591 604.
30. Tigani B, Cannet C, Zurbrugg S, Schaeublin E, Mazzoni L, Fozard JR et al 2003). Resolution of the oedema associated with allergic pulmonary inflammation in rats assessed noninvasively by magnetic resonance imaging. Br J Pharmacol 140 : 239 246.
31. Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS (2008). Molecular imaging in drug development. Nat Rev Drug Discov 7 : 591 607.